Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2337/diabetes.52.11.2652 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Canada and the United States are both aging and becoming increasingly diverse. Despite this demographic shift, non-White racial/ethnic groups remain underrepresented in research on cognitive impairment and dementia. A major barrier to inclusivity is the lack of cognitive assessments that are valid in individuals with diverse language and cultural backgrounds.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Institute of Neurosciences. Department of Biomedicine, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
Large neuroimaging datasets play a crucial role in longitudinal modelling and prediction of neurodegenerative diseases, as they provide the opportunity to study biomarker trajectories over time. Noteworthy, the availability of these large datasets coexists with a paradigm shift in the theoretical understanding of these diseases: while classical studies aimed at defining disease signatures as group patterns obtained with static cross-sectional analyses, novel approaches focus on providing individual predictions in the context of phenotypical and temporal heterogeneity. This scenario is often aggravated by the fact that datasets are not homogeneous and suffer from missing points and noisy data.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
The William H. Annesley, Jr, EyeBrain Center, Farber Neuroscience Institute at Thomas Jefferson University, Philadelphia, PA, USA.
Background: FLIO a novel in vivo reproducible, non-invasive imaging technology, measures fluorescence lifetime decay in two spectral channels for short-lived retinal chromophores in two domains: Channel 1 emission wavelength 498-560 nm corresponding to NADH and FAD/ATP function and Channel 2, 560-720 nm wavelength corresponding to lipofuscin/lysosomal function. These data reflect the retinal mitochondrial molecular environment. Mitochondrial dysfunction has been recently explored as a cause of decreased synaptic function and cognitive decline in AD.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Background: Alzheimer's disease (AD) is associated with cerebral slowing on electroencephalography (EEG), or a shift in oscillatory power from higher to lower frequencies. This change can be captured as the spectral power ratio (SPR) of alpha and beta over delta and theta: (α+β)/(δ+θ). Prior studies have shown that compared to cognitively unimpaired older adults, the SPR was lower in persons with a clinical diagnosis of dementia due to probable AD and those with a biomarker-confirmed diagnosis of amnestic mild cognitive impairment (aMCI) due to AD, and a lower SPR was associated with worse executive functions scores.
View Article and Find Full Text PDFAlzheimer's Imaging Consortium.
Alzheimers Dement
December 2024
RIKEN Center for Biosystems Dynamics Research, Suita-shi, Osaka, Japan.
Background: In aging societies, neurodegenerative diseases, such as Alzheimer's disease, are receiving attention. These diseases are primary targets for preemptive medicine, emphasizing the importance of early detection and preventive treatment before the onset of severe, treatment-resistant damages. However, there is a lack of comprehensive investigation of lesions and molecular targets in the entire organ, whereas spatial identification of early-stage lesions is potentially overlooked at the single-cell level.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!